Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since

Eli Lilly (LLY) has finalized a strategic drug pricing agreement with the government, offering a 55% discount on its leading weight loss drugs, Zepbound and Mounjaro, for Medicare coverage starting April 2026. This move is expected to unlock a vast new market for Lilly while crucially protecting its more lucrative commercial pricing channels with private insurers. In exchange, the company secured a three-year tariff exemption and a Commissioner's National Priority Voucher for its oral weight loss candidate, orforglipron, which could dramatically accelerate its FDA review to as little as one to two months. The market has reacted positively, with LLY shares gaining 10% since the announcement, and analysts raising price targets, signaling confidence that the deal positions Lilly for significant volume growth and expedited market entry for a potential blockbuster drug.

Analysis

Eli Lilly (LLY) has finalized a strategic drug pricing agreement, offering a 55% discount on Zepbound and Mounjaro for Medicare coverage starting April 1, 2026, pricing them at $245. This concession is expected to unlock a vast new market through Medicare and Medicaid, which currently represent a small fraction of Lilly's sales volume, while crucially protecting its lucrative private insurer channels from mandatory price cuts.

In exchange, Lilly secured significant non-monetary benefits, including a three-year tariff exemption, mitigating previous stock concerns. Furthermore, a Commissioner's National Priority Voucher for its oral weight loss candidate, orforglipron, could accelerate its FDA review from 10-12 months to just 1-2 months. This expedited pathway dramatically improves orforglipron's commercial outlook, potentially bringing another blockbuster drug to market much sooner.

The market has responded positively, with LLY shares gaining 1.3% on the announcement day and a total of 10% by November 12, outperforming broader indices. Wall Street analysts, including BMO Capital Markets, UBS Group, and Leerink Partners, have largely validated this optimism, raising price targets. The post-Nov 6 average analyst target now implies a 5% upside, reversing a prior consensus of 3% downside.

Key Decisions for Investors

• Monitor the implementation of the Medicare pricing strategy and its impact on LLY's volume growth and net revenue post-April 2026.
• Track the expedited FDA review process for orforglipron, as its potential early approval could significantly enhance Lilly's long-term growth trajectory and market share in the weight loss segment.
• Assess LLY's sustained outperformance against the broader healthcare sector, considering its strengthened competitive position and protected commercial pricing channels.